NIH-funded research R01 grant

New Ways to Treat Depression with Ketamine-Related Medicines

Official title: Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment

Funded at University of Maryland Baltimore · NIH-11367134 · Data updated 2026-11-12

This research explores how parts of ketamine, called metabolites, might offer a faster and safer way to help people with major depression.

More Depression research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Maryland Baltimore
NIH-funded
Lab location1 site (Baltimore, United States)
Project startApril 1, 2016
Project endJanuary 31, 2027
Funding year2025
Award (this year)$60,205
NIH project number3R01MH107615-10S1
Project IDNIH-11367134 on NIH RePORTER

Who could benefit from this research

Could help

Patients who experience major depressive disorder, especially those who have not found relief with traditional antidepressant treatments, could potentially benefit from future therapies developed from this research.

Less likely to help

Patients who do not have major depressive disorder or who respond well to existing antidepressant medications may not directly benefit from this specific line of research.

What this research studies

Many people with major depression find that current medications take a long time to work, or don't work well enough. Ketamine has shown promise as a fast-acting antidepressant, but it can have unwanted side effects. This project looks at specific parts of ketamine, called metabolites, to see if they can provide the antidepressant benefits without the side effects. By understanding how these metabolites work, we hope to create new and better medicines for depression.

Why it matters

Potential benefit: If successful, this work could lead to new, fast-acting antidepressant medications with fewer side effects, offering quicker relief for patients.

How similar studies have gone: Ketamine itself has demonstrated rapid antidepressant effects in patients, and this research builds on those findings by focusing on its metabolites to improve safety.

Where this research is happening

  • University of Maryland Baltimore
    Baltimore, United States
    Active

Researchers

  • Principal investigator: Gould, Todd D — University of Maryland Baltimore
  • Study coordinator: Gould, Todd D

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.